SCHEMBL6792353

SCHEMBL6792353

CC(C)(C)OC(=O)N1CCN(c2ccc(Br)cn2)C1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN5A Q14524 1/20 0.45
SCN9A Q15858 1/20 0.45
DDB1 Q16531 1/20 0.38
CRBN Q96SW2 1/20 0.38
AKR1C3 P42330 1/20 0.38
PPARG P37231 1/20 0.37
PPARD Q03181 1/20 0.37
PPARA Q07869 1/20 0.37
DGAT1 O75907 1/20 0.37
MAP4K4 O95819 1/20 0.36
CPB2 Q96IY4 1/20 0.36
HDAC1 Q13547 1/20 0.36
CKS1B P61024 1/20 0.35
SKP1 P63208 1/20 0.35
SKP2 Q13309 1/20 0.35
GPR119 Q8TDV5 3/20 0.35
RET P07949 1/20 0.35
ELANE P08246 1/20 0.35
KDM4E B2RXH2 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL974575 0.85 HDAC1 (0.43) SCN5ASCN9APPARGPPARDPPARA
SCHEMBL15205695 0.83 MAP4K4 (0.42) DDB1CRBNAKR1C3MAP4K4CKS1B
SCHEMBL29522264 0.81 AKR1C3 (0.44) DDB1CRBNAKR1C3PPARGPPARD
SCHEMBL15206161 0.81 AKR1C3 (0.44) DDB1CRBNAKR1C3PPARGPPARD
SCHEMBL23967052 0.78 SCN9A (0.48) SCN5ASCN9AMAP4K4HDAC1CKS1B
SCHEMBL3029736 0.77 SCN5A (0.44) SCN5ASCN9ADDB1CRBNMAP4K4
SCHEMBL16698455 0.76 SCN5A (0.45) SCN5ASCN9AMAP4K4HDAC1CKS1B
SCHEMBL30480343 0.76 AKR1C3 (0.57) DDB1CRBNAKR1C3PPARGPPARD
SCHEMBL594352 0.76 AKR1C3 (0.57) DDB1CRBNAKR1C3PPARGPPARD
SCHEMBL13100992 0.76 AKR1C3 (0.51) DDB1CRBNAKR1C3PPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6689779-B2 PYRIDINE OR PYRIMIDINE SUBSTITUTED; ANTIBACTERIAL ACTIVITY; LOW TOXICITY DONG A PHARM. CO., LTD. (KR) 2004-02-10 US disclosed
US-20030166620-A1 Novel oxazolidinone derivatives and a process for the preparation thereof DONG A PHARM. CO., LTD. (KR) 2003-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166620-A1 Novel oxazolidinone derivatives and a process for the preparation thereof OXA1L, ODC1, PDCD4 SCN5A 3119/4885SCN9A 4377/4885DDB1 828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.